New NIH plan outlines HSV research framework with four strategic priorities

In response to the persistent health challenges of herpes simplex virus 1 (HSV-1) and HSV-2, today the National Institutes of Health released the Strategic Plan for Herpes Simplex Virus Research.

FDA Panel Mulls Which Devices Are Critical in a Public Health Emergency

What bare minimum equipment would you need to practice your specialty during a public health emergency? It depends on what the emergency is, members of

February 7, 2024

EC approves TECVAYLI’s reduced dosage for multiple myeloma

Janssen’s Teclistamab is a bispecific antibody directed at B-cell maturation antigen on multiple myeloma cells. Credit: Vysotsky / commons.wikimedia.org. The European Commission (EC) has approved

August 21, 2023

Mustang Bio’s MB-108 receives FDA orphan drug status for glioma treatment

MB-108 is an oncolytic virus designed to treat malignant glioma. Credit: meeboonstudio via Shutterstock. Mustang Bio has received orphan drug designation from the US Food

November 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.